Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADAG Adagene

Market Closed 03-20 16:00:00 EDT

3.63

-0.06

-1.63%

盘后3.63

+0.000.00%

16:25 EDT

High3.86	Low3.53	Vol141.44K
Open3.69	D1 Closing3.69	Amplitude8.94%
Mkt Cap171.09M	Tradable Cap46.22M	Total Shares47.13M
T/O517.80K	T/O Rate1.11%	Tradable Shares12.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADAG","market":"US","secType":"STK","nameCN":"Adagene","latestPrice":3.63,"timestamp":1774036800000,"preClose":3.69,"halted":0,"volume":141437,"hourTrading":{"tag":"盘后","latestPrice":3.63,"preClose":3.63,"latestTime":"16:25 EDT","volume":9,"amount":32.46,"timestamp":1774038345791,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.016260162601626032,"floatShares":12732488,"shares":47131300,"eps":-0.642762,"marketStatus":"Market Closed","change":-0.06,"latestTime":"03-20 16:00:00 EDT","open":3.69,"high":3.86,"low":3.53,"amount":517795.295724,"amplitude":0.089431,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.642762,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"adrRate":1.25,"listingDate":1612846800000,"exchange":"NASDAQ","adjPreClose":3.69,"postHourTrading":{"tag":"盘后","latestPrice":3.63,"preClose":3.63,"latestTime":"16:25 EDT","volume":9,"amount":32.46,"timestamp":1774038345791,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6464757542847952},"requestUrl":"/m/hq/s/ADAG","defaultTab":"news","newsList":[{"id":"2620673656","title":"Adagene Inc  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620673656","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620673656?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:40","pubTimestamp":1774010418,"startTime":"0","endTime":"0","summary":"Adagene Inc  expected to post a loss of15cents a share - Earnings Preview Adagene Inc ADAG.OQ, ADAG.O is expected to  report resultson March 23 (estimated) for the period ending September 30 2025LSEG'","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40815N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"gpt_icon":0},{"id":"2620825983","title":"Adagene Inc. files Form 3 initial beneficial ownership statement for CFO and Director Man Kin Tam","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825983","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825983?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:05","pubTimestamp":1773839125,"startTime":"0","endTime":"0","summary":"Adagene reported an initial statement of beneficial ownership by Man Kin Tam, who serves as chief financial officer and a director. Tam reported direct ownership of 116,583 ordinary shares. Tam also reported 37,500 restricted stock units. The filing listed nonqualified stock options covering 252,448 ordinary shares with an exercise price of USD 1.73.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7W3GDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"gpt_icon":0},{"id":"2620256775","title":"Adagene Inc. CEO and Director Peter Luo Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620256775","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620256775?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:05","pubTimestamp":1773839105,"startTime":"0","endTime":"0","summary":"Adagene reported an initial statement of beneficial ownership by Peter Luo, its chief executive officer and a director. Peter Luo beneficially owned 93,264 ordinary shares directly, and 31,021 ordinary shares indirectly through his spouse. He also reported 168,750 restricted stock units directly, and 75,000 restricted stock units indirectly through his spouse. In addition, he reported incentive stock options covering 287,415 ordinary shares at an exercise price of USD 13.85. He also reported incentive stock options covering 822,819 ordinary shares at an exercise price of USD 1.73.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Ga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL18N1Qr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG","BK4139"],"gpt_icon":0},{"id":"2620026256","title":"Adagene Inc. ED of Human Resources Zhou Ling Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620026256","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620026256?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:04","pubTimestamp":1773839076,"startTime":"0","endTime":"0","summary":"Adagene reported an initial statement of beneficial ownership by Zhou Ling, an officer serving as Executive Director of Human Resources. Zhou held 2,969 ordinary shares. Zhou also held 9,375 restricted stock units. Zhou reported nonqualified stock options covering 25,000 ordinary shares at a USD 1.48 exercise price. Zhou also reported nonqualified stock options covering 35,000 ordinary shares at a USD 2.03 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8fJjsn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"gpt_icon":0},{"id":"2620625670","title":"Adagene Inc. files initial beneficial ownership statement for Chief Manufacturing Officer Zhao Qinghai","url":"https://stock-news.laohu8.com/highlight/detail?id=2620625670","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620625670?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:02","pubTimestamp":1773838943,"startTime":"0","endTime":"0","summary":"Adagene reported an initial statement of beneficial ownership for Zhao Qinghai, its Chief Manufacturing Officer. Zhao beneficially owned 130,214 ordinary shares. Zhao also held 37,500 restricted stock units.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL47mVkF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"gpt_icon":0},{"id":"2620206256","title":"Adagene Inc. Director Do Cuong V Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620206256","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620206256?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:01","pubTimestamp":1773838917,"startTime":"0","endTime":"0","summary":"Adagene reported an initial statement of beneficial ownership by director Cuong Do. Cuong Do disclosed an incentive stock option for 40,000 ordinary shares with an exercise price of USD 0.8. He also disclosed a nonqualified stock option for 50,000 ordinary shares with an exercise price of USD 1.07.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8KdMLb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"gpt_icon":0},{"id":"2620524403","title":"Adagene to present two ADG126 posters at AACR annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620524403","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620524403?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779726,"startTime":"0","endTime":"0","summary":"Adagene to present two ADG126 posters at AACR annual meeting               Adagene will present two posters on muzastotug (ADG126) at the AACR Annual Meeting in San Diego, California, held April 17-22","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL3tWmk6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BN0W2W23.USD","ADAG","LU2210150020.SGD","IE00BGHQF748.EUR","BK4585","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","NDAQ","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4139"],"gpt_icon":0},{"id":"2620040191","title":"Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040191","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040191?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779700,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, March  17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257692/0/en/Adagene-s-Muzastotug-ADG126-to-be-Highlighted-in-Two-Presentations-at-the-2026-American-Association-for-Cancer-Research-AACR-Annual-Meeting-in-San-Diego-CA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","ADAG","CA","BK4139","BK4113","HCC","LU0266512127.USD","BK4006","BK4213","AFG","CRC","BK4117","LU0456854461.SGD","MSS"],"gpt_icon":0},{"id":"2620542735","title":"Adagene Inc. Director Ulf Grawunder Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620542735","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620542735?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:57","pubTimestamp":1773752222,"startTime":"0","endTime":"0","summary":"Adagene said director Ulf Grawunder filed an initial statement of beneficial ownership on 03/17/2026. The filing reported 25,000 ordinary shares held directly. It also reported nonqualified stock options for 40,000 ordinary shares with an exercise price of USD 2.26. The filing also reported nonqualified stock options for 25,000 ordinary shares with an exercise price of USD 2.03.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9vPcSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG","BK4139"],"gpt_icon":0},{"id":"2612468956","title":"Adagene to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2612468956","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612468956?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:27","pubTimestamp":1771338420,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, Feb.  17, 2026  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239418/0/en/Adagene-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC","BK4213","BK4113","LU0266512127.USD","LU0456854461.SGD","MSS","ADAG","BK4139"],"gpt_icon":0},{"id":"2611145230","title":"Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Tyra Bioscience (TYRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611145230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611145230?lang=en_us&edition=fundamental","pubTime":"2026-02-15 02:20","pubTimestamp":1771093207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adagene (ADAG – Research Report) and Tyra Bioscience...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-adagene-adag-and-tyra-bioscience-tyra-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-adagene-adag-and-tyra-bioscience-tyra-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0029874061.USD","LU0128526141.USD","BK4581","TYRA","HCSG","ADAG","BK4137","BK4588","XBI","LABU","BK4139","XLV"],"gpt_icon":0},{"id":"2610035465","title":"Adagene (ADAG): De-Risked CTLA-4 Asset, Emerging Regulatory Clarity, and Strategic Partnerships Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2610035465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610035465?lang=en_us&edition=fundamental","pubTime":"2026-02-09 06:16","pubTimestamp":1770588960,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Charles Zhu has maintained their bullish stance on ADAG stock, giving a Buy rating on February 4. Charles Zhu has given his...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adagene-adag-de-risked-ctla-4-asset-emerging-regulatory-clarity-and-strategic-partnerships-underpin-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adagene-adag-de-risked-ctla-4-asset-emerging-regulatory-clarity-and-strategic-partnerships-underpin-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG"],"gpt_icon":0},{"id":"2606217744","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Adagene (ADAG) and Johnson & Johnson (JNJ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606217744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606217744?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:20","pubTimestamp":1769430030,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Maze Therapeutics, Inc. (MAZE – Research Report), Adagene (ADAG –...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-maze-therapeutics-inc-maze-adagene-adag-and-johnson-johnson-jnj-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-maze-therapeutics-inc-maze-adagene-adag-and-johnson-johnson-jnj-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU1066051498.USD","LU1066051811.HKD","XLV","IE00B19Z3B42.SGD","IE00BFXG1179.USD","BK4139","LU1061106388.HKD","LU2129689514.USD","LU0234572021.USD","XBI","LU0345770308.USD","IE00B42XCP33.USD","LU2592432038.USD","LU1244550494.USD","LU0912757837.SGD","IE00BKVL7J92.USD","BK4581","LU1023059063.AUD","LU0058720904.USD","LU1778281490.HKD","JNJ","LU0689626769.HKD","IE00BFTCPJ56.SGD","LU1935042991.SGD","LU2750360997.AUD","LU1221951046.USD","LU0203345920.USD","LU0345769631.USD","BK4588","IE00BVYPNV92.GBP","LABU","IE00B2B36J28.USD","IE0009355771.USD","LU0345770993.USD","LU1059921491.USD","LU1057294990.SGD","LU1674673428.USD","MAZE","BK4534","LU1066053197.SGD","LU0234570918.USD","LU0795875169.SGD","LU0345769128.USD","LU2750360641.GBP","LU0203347892.USD","HCSG","SG9999001440.SGD","BK4137","ADAG"],"gpt_icon":0},{"id":"2606943922","title":"Adagene Reports $74.5 Million Year-End Cash and Sets 2026 Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2606943922","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606943922?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:03","pubTimestamp":1769411011,"startTime":"0","endTime":"0","summary":"Adagene Inc. announced a business update and provided its 2026 objectives. As of December 31, 2025, the company reported unaudited cash and cash equivalents of $74.5 million, which is anticipated to provide sufficient financial runway into late 2027. The company highlighted its progress in 2025, including a collaboration with ConjugateBio on bispecific antibody-drug conjugates  using Adagene-derived antibodies. For 2026, Adagene plans to provide a data update in Q1 from its ongoing Phase 1b/2 study of muzastotug in combination with pembrolizumab for third-line and later (3L+) microsatellite stable colorectal cancer  patients, covering 41 patients in the 10 mg/kg cohorts and 26 patients in the 20 mg/kg cohorts. The reported cash position is preliminary, unaudited, and subject to finalization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL9CZvjY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014021.USD","IE00BKPKM429.USD","ADAG","BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","BK4112","IE00B64PRP62.GBP","BK4139","SG9999014039.USD"],"gpt_icon":0},{"id":"2605847027","title":"Press Release: Adagene Provides Business Update and 2026 Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2605847027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605847027?lang=en_us&edition=fundamental","pubTime":"2026-01-23 21:00","pubTimestamp":1769173200,"startTime":"0","endTime":"0","summary":"Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026. Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to provide sufficient runway into late 2027. SAN DIEGO and SUZHOU, China, Jan. 23, 2026  -- Adagene Inc.  , a company transforming the discovery and development of novel antibody-based therapies, today announced year-end unaudited cash and cash equivalents of $74.5 million and provided a business update.-- Phase 1b/2 trial results with muzastotug in MSS CRC at ASCO: Shared. updated data from 10 mg/kg and 20 mg/kg cohorts at ASCO 2025,demonstrating a favorable safety profile at 10-20x times higher dosing. than first generation CTLA-4 inhibitors. Encouraging overall response. rates and durable responses suggest potential for long-term survival. -- FDA Fast Track designation for muzastotug in combination with Merck's. selection, trial design, patient population and endpoint","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4113","03160","BK4099","BK4213","BK4555","MSS","R","LU0456854461.SGD","BK4604","ADAG","BK4588","CRC","BK4585","BK4232","LU0266512127.USD","TM","BK4022"],"gpt_icon":0},{"id":"2604116504","title":"LifeSci Capital Sticks to Their Buy Rating for Adagene (ADAG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116504?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:39","pubTimestamp":1768916350,"startTime":"0","endTime":"0","summary":"In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Adagene, with a price target of $8.00. According to TipRank...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-their-buy-rating-for-adagene-adag-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-their-buy-rating-for-adagene-adag-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG"],"gpt_icon":0},{"id":"2592932150","title":"Adagene's Muzastotug Gets FDA Fast Track in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2592932150","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592932150?lang=en_us&edition=fundamental","pubTime":"2025-12-17 04:24","pubTimestamp":1765916664,"startTime":"0","endTime":"0","summary":"Adagene  said the US Food and Drug Administration granted Fast Track designation to its muzastotug drug in combination with Merck's  Keytruda for treating adults with microsatellite-stable metastatic colorectal cancer without active liver metastases.The designation is supported by early data showing efficacy, durable responses and safety, and allows for the possibility of a rolling review of future marketing applications, Adagene said Tuesday in a statement.Adagene plans to continue its randomized Phase 2 trial and expects a registration-enabling Phase 3 study to start in 2027.The company's shares rose 3.6% in recent Tuesday trading.Price: 1.73, Change: +0.06, Percent Change: +3.59","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1929549753.HKD","LU1430594728.SGD","LU0320765646.SGD","LU0477156953.USD","LU2125154935.USD","LU0130517989.USD","LU2023250843.SGD","IE00BJJMRZ35.SGD","LU0130102774.USD","LU1116320737.USD","IE0009355771.USD","LU0289739699.SGD","LU1941712348.USD","LU1989772840.SGD","BK4559","LU0098860793.USD","SG9999002224.SGD","SG9999015358.SGD","LU0058720904.USD","LU0106261372.USD","LU1069347547.HKD","LU1023059063.AUD","IE00BLSP4452.SGD","LU0070302665.USD","LU1291159041.SGD","LU1585245621.USD","IE0002141913.USD","LU2125154778.USD","IE00BN8TJ469.HKD","LU0203345920.USD","IE00B1BXHZ80.USD","LU0980610538.SGD","SG9999001176.SGD","LU0238689110.USD","LU1989772923.USD","LU1162221912.USD","LU1941712264.USD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU0265550946.USD","LU1983299246.USD","LU2361044865.SGD","LU0203347892.USD","LU1116320901.HKD","LU1699723380.USD","LU0965509283.SGD","SG9999014559.SGD","LU0234572021.USD","LU0266013472.USD","LU0122379950.USD","IE00B4R5TH58.HKD","LU0965509101.SGD","SG9999013999.USD","SG9999001176.USD","SGXZ57979304.SGD","IE00B2B36J28.USD","LU2089984988.USD","LU0211331839.USD","LU2106854487.HKD","BK4139","LU1066051811.HKD","LU1934455277.USD","LU1066051498.USD","LU1934455194.USD","SG9999015341.SGD","IE000M9KFDE8.USD","SG9999014542.SGD","LU0648001328.SGD","LU1061106388.HKD","BK4585","LU1201861249.SGD","LU0965508806.USD","LU0861579265.USD","LU2461242641.AUD","LU1571399168.USD","BK4550","BK4007","IE00BJT1NW94.SGD","BK4516","SG9999002232.USD","LU1093756168.USD","BK4533","LU2112291526.USD","LU0985320562.USD","LU1035773651.USD","LU2361044949.HKD","LU0208291251.USD","LU0320765489.SGD","SG9999014567.USD","IE00BLSP4239.USD","LU1037948541.HKD","BK4534","LU1917777945.USD","LU1974910355.USD","LU2324357040.USD","LU1934455863.HKD","LU0265550359.USD","LU2360032135.SGD","LU0965509010.AUD","LU1066051225.USD","SG9999001440.SGD","LU1037948897.HKD","LU0006306889.USD","LU1989771016.USD","LU2023250504.SGD","IE00BBT3K403.USD","LU1093756325.SGD","ADAG","LU2361045086.USD","BK4588","LU1066053197.SGD","LU1057294990.SGD","LU2468319806.SGD","SG9999014575.USD"],"gpt_icon":0},{"id":"2591981565","title":"Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981565","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981565?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:18","pubTimestamp":1765887529,"startTime":"0","endTime":"0","summary":"Dec 16 (Reuters) - Adagene Inc <978y.F>::*ADAGENE ANNOUNCES FDA FAST TRACK DESIGNATION FOR MUZASTOTUG (ADG126)  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 16-DEC-202512:00:00.697 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nRSD6gmtB6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"gpt_icon":0},{"id":"2591894279","title":"Adagene Reports Promising Responses for Muzastotug in Combination with Pembrolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2591894279","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591894279?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:01","pubTimestamp":1765886478,"startTime":"0","endTime":"0","summary":"Adagene Inc. has announced that its anti-CTLA-4 therapy, muzastotug , developed using the company's proprietary SAFEbody technology, has received FDA Fast Track Designation for the treatment of microsatellite stable  colorectal cancer. The company highlighted encouraging responses seen with muzastotug in combination with pembrolizumab, suggesting the potential to improve survival and quality of life for patients. Adagene stated that updated topline Phase 1b/2 clinical data will be shared in the coming months, as the program progresses towards a Phase 3 trial with overall survival as the primary endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via Globe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLs8Q0g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","BK4588","ADAG","LU2095319765.USD","SG9999014013.SGD","BK4139","IE00B3QW5Z07.USD","BK4585","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2585902467","title":"Adagene Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2585902467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585902467?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:40","pubTimestamp":1763991600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 08:40 ET (13:40 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG","BK4139"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1211},{"period":"1month","weight":0.1033},{"period":"3month","weight":0.9945},{"period":"6month","weight":0.7707},{"period":"1year","weight":1.0393},{"period":"ytd","weight":0.9206}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Their platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity. These features enable their novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. They have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Their platform is designed to enable the rapid development of precision immunotherapy candidates, through the identification of predictive biomarkers for patient stratification and preselection.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.330237},{"month":2,"riseRate":0.4,"avgChangeRate":-0.074707},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.149141},{"month":4,"riseRate":0.2,"avgChangeRate":-0.086636},{"month":5,"riseRate":0.6,"avgChangeRate":0.052249},{"month":6,"riseRate":0.6,"avgChangeRate":-0.017271},{"month":7,"riseRate":0.4,"avgChangeRate":-0.053125},{"month":8,"riseRate":0.6,"avgChangeRate":0.014607},{"month":9,"riseRate":0.2,"avgChangeRate":-0.076447},{"month":10,"riseRate":0.2,"avgChangeRate":-0.090108},{"month":11,"riseRate":0.6,"avgChangeRate":0.034268},{"month":12,"riseRate":0.4,"avgChangeRate":0.020923}],"exchange":"NASDAQ","name":"Adagene","nameEN":"Adagene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adagene(ADAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adagene,ADAG,Adagene股票,Adagene股票老虎,Adagene股票老虎国际,Adagene行情,Adagene股票行情,Adagene股价,Adagene股市,Adagene股票价格,Adagene股票交易,Adagene股票购买,Adagene股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adagene(ADAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction